Drospirenone-containing OCs under review for VTE

被引：0

作者：

机构：

来源：

Reactions Weekly | 2011年 / 1355卷 / 1期

关键词：

Potential Risk; Healthcare Professional; Oral Contraceptive; Venous Thromboembolism; Product Information;

D O I：

10.2165/00128415-201113550-00002

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[21] 3rd-generation OCs significantly associated with VTE
Reactions Weekly, 2002, 904 (1) : 5 - 5
[22] Increased VTE risk of third-generation OCs not supported
Reactions Weekly, 2000, 816 (1) : 5 - 5
[23] Drospirenone ups risk of VTE, PE, but not TIA, stroke
Reactions Weekly, 2011, 1382 (1) : 2 - 2
[24] Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
Dinger, Juergen
Assmann, Anita
Moehner, Sabine
Minh, Thai Do
JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2010, 36 (03) : 123 - 129
[25] No extra VTE risk with 24-day ethinylestradiol/drospirenone
Reactions Weekly, 2010, 1326 (1) : 3 - 3
[26] `Third-generation' OCs and VTE: biases could explain the increased risk
Reactions Weekly, 1997, 635 (1) : 3 - 3
[27] FDA concludes drospirenone safety review
Reactions Weekly, 2012, 1398 (1) : 2 - 2
[28] VTE risk with third-generation OCs may be lower
Reactions Weekly, 1997, 665 (1) : 2 - 2
[29] Low-dose estrogen combined OCs increase VTE risk
Reactions Weekly, 2004, 1014 (1) : 5 - 5
[30] No difference in VTE risk between second- and third-generation OCs
Reactions Weekly, 1997, 678 (1) : 6 - 6

← 1 2 3 4 5 →